Peer-influenced content. Sources you trust. No registration required. This is HCN.

Cancer Therapy AdvisorMonoclonal Antibody Shows Promise for Treating MPNs in Preclinical Study

A fully human IgG1 antibody that selectively binds to mutant CALR, INCA033989 demonstrated activity in cells from MPN patients and a mouse model of essential thrombocythemia. In the model, INCA033989 selectively decreased levels of mutant CALR-positive platelets, re-established normal megakaryopoiesis, and selectively targeted mutant CALR disease-initiating clones.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form